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 2 
ABSTRACT 20 
Background and objective: Pregnant women were a priority group for vaccination during the 2009 21 
A(H1N1) influenza pandemic. In France, vaccination was organized in ad hoc centers. Women 22 
received vouchers by mail and were given a non-adjuvanted vaccine. Our objective was to assess the 23 
national vaccination rate among pregnant women and to determine the association of vaccination with 24 
maternal characteristics, prenatal care, and pregnancy-related health behaviors.   25 
Method: Data came from a national representative sample of women who gave birth in March 2010 26 
(N=13 453) and were interviewed in the hospital before discharge; they were in the second trimester of 27 
pregnancy during the vaccination campaign. Associations between vaccination and socio-28 
demographic and medical characteristics, region of residence, care providers, and preventive 29 
behaviors were assessed with bivariable analyses and logistic regression models.  30 
Results: Vaccine coverage was 29.3% (95% CI: 28.6-30.1). The main reason for not being vaccinated 31 
was that women did not want this immunization (91%). In adjusted analyses, vaccination was more 32 
frequent in women who were older, employed, born in France, with a parity of 1 or 2 and specific 33 
favourable health behaviors. The adjusted odds ratio for women with a postgraduate educational level 34 
was 4.1 (95% CI: 3.5-4.8) compared to those who did not complete high school. Women with 35 
additional risk factors for complications from A(H1N1) infection had a vaccination rate similar to that of 36 
other women.  37 
Conclusion: The vaccination campaign resulted in poor vaccination coverage, strong social 38 
inequalities, and no special protection for pregnant women at the highest risk of complications. These 39 
findings provide essential information for the organization of future vaccination campaigns. 40 
 41 
Keywords: A(H1N1) influenza; vaccination; pregnant women; maternal characteristics; health 42 
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INTRODUCTION 45 
The consequences of pandemic and seasonal influenza during pregnancy are well known [1]. 46 
Particularly serious effects of A(H1N1) influenza on pregnant women and newborns were reported at 47 
the very beginning of the pandemic in July 2009 [2] and were subsequently confirmed [3-4].  48 
International organizations [5-6] advised that all pregnant women be vaccinated against the 2009 49 
A(H1N1) flu, regardless of the type of vaccine or the trimester of pregnancy. In France, vaccination 50 
was recommended for the entire population and priority vaccination for some groups at high risk, 51 
including pregnant women in the second and third trimesters of pregnancy [7]. A non-adjuvanted 52 
vaccine (Panenza®) was recommended for this group, based on doubts about potential risks for 53 
fetuses, in contrast with most European countries which used adjuvanted vaccines [8]. The non-54 
adjuvanted vaccine did not become available until November 20, 2009, ie, one month after the 55 
beginning of the epidemic [9] and the beginning of the vaccination campaign for the general population 56 
[10]. Vaccination was free and was performed most often in special ad hoc vaccination sites, such as 57 
local gymnasiums. During the 10 days before the non-adjuvanted vaccine became available, all 58 
pregnant women received invitations with vouchers by mail, with a list of vaccination centers close to 59 
their home. 60 
The French vaccination campaign took place in a generally unfavorable climate, with heated debates 61 
about the utility and risks of vaccination. This resulted in low acceptability of the vaccine [11] and only 62 
7.9% of the general population was vaccinated [12].  63 
Our objectives were to estimate the national rate of vaccination against A(H1N1) influenza in pregnant 64 
women and to assess whether vaccination uptake was associated with maternal socio-demographic 65 
and medical characteristics, prenatal care, and other maternal health-related behaviors. We used the 66 
National Perinatal Survey, carried out in March 2010, to study these questions. 67 
 68 
METHODS 69 
The National Perinatal Surveys are conducted routinely to monitor perinatal health. They include all 70 
births in one week in all maternity units [13]. Women are interviewed between delivery and discharge 71 
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about their socio-demographic characteristics, prenatal care and health behavior. Data on health and 72 
obstetric care are collected from medical records. In the 2010 survey, women were asked whether 73 
they had been vaccinated against A(H1N1) influenza and, if not, why not. The sample included 14,355 74 
women in mainland France and vaccination uptake was known for 13,453 women. 75 
We studied several categories of determinants of vaccination uptake: maternal socio-demographic 76 
characteristics, medical characteristics, prenatal care and health behaviors. The medical 77 
characteristics included conditions associated with complications during influenza infection (e.g., 78 
diabetes mellitus, asthma, respiratory or renal failure, chronic hepatitis B and C infections, and BMI 79 
>30) [14-15]. In addition, we identified women belonging to priority groups for vaccination, 80 
independently of pregnancy [7]: those in contact with children (e.g., teachers and daycare personnel) 81 
and those in the health-care sector (e.g., doctors, nurses, and nurses' aides).  82 
The prenatal care characteristics were the number of prenatal visits (classified with respect to the 83 
minimum number of visits recommended in France according to the duration of pregnancy), the care 84 
provider at the beginning of pregnancy (obstetrician/gynecologist, general practitioner, or midwife), 85 
and the use of public or private care. We considered that care was mainly in the private sector if the 86 
woman delivered in a private maternity unit, because most of those women receive prenatal care from 87 
a private obstetrician/gynecologist associated with the unit.  88 
We studied the following health behaviors: consumption of folic acid in periconceptional period, not 89 
smoking during the third trimester of pregnancy, and participating in antenatal classes. 90 
We first assessed the vaccination rate and then studied the factors associated with vaccination 91 
uptake. Variables were studied using a bivariate and then a logistic regression analysis. The final 92 
model included all the variables which were associated with vaccination at the previous step (p value 93 
<0.10). Risk factors for complications from flu infection and high-risk occupations were kept in the 94 
model, regardless of the association at the previous stage of analysis. SAS 9.2 software was used for 95 




 Almost all women (99%) were in the second trimester of pregnancy when the non-adjuvanted vaccine 99 
became available. The vaccination rate was 29.3% (95% CI: 28.6-30.1). The main reasons that 100 
women reported that they were not vaccinated were: not wanting the vaccine (91.2%), not offered a 101 
vaccination (5.3%), already had flu symptoms (1.0%), practical reasons (1.6%), and other reasons 102 
(0.9%). 103 
The vaccination rate was higher in older women, in those with parity less than 3, and in those without 104 
any risk factor for complications from flu infection (Table 1). Married women, those with a higher 105 
educational level, born in France, employed during pregnancy, or at high risk of flu exposure or 106 
transmission because of their occupation were also vaccinated more frequently. Among healthcare 107 
workers, the vaccination rate was 84% among medical doctors, pharmacists, and dentists, 46% 108 
among nurses, midwives, and physical therapists, and 24% in women in less skilled occupations. 109 
Variations were also found between regions (results not shown).  110 
The vaccination rate was very low for women who had fewer than the minimum number of visits 111 
required by French regulations; it was also lower in women who had care provided by GPs and who 112 
had prenatal care mainly in the public sector. Vaccination was less frequent among women who did 113 
not take folic acid in the periconception period, who smoked during pregnancy and who did not attend 114 
antenatal classes.  115 
In the adjusted model, risk factors for complications and number of prenatal visits were not associated 116 
with vaccination. The odds ratio for women with a postgraduate educational level was 4.1 (3.5-4.8), 117 
compared to those who did not complete high school; the odds ratios were between 0.6 and 0.8 for 118 
women under 25 year old compared to older women, for single women compared to married women, 119 
and for women who were born abroad compared to native born women. There was lower vaccination 120 
coverage in several regions, including Paris and its metropolitan area (data available on request). 121 
 122 
DISCUSSION 123 
 In 2009, the rate of vaccination against 2009 A(H1N1) influenza among pregnant women in France 124 
was quite low. It was higher among women with a high educational level and those with positive health 125 
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behavior during pregnancy. Having medical characteristics associated with the risk of severe influenza 126 
complications did not influence the vaccination rate. 127 
The principal strength of our study is that it provides data about a representative national sample of 128 
women [13] in the second trimester of pregnancy during the vaccination campaign. Very few European 129 
countries were able to provide precise population-based estimates of vaccine coverage among 130 
pregnant women [8]. Nonetheless, given the number of topics covered by the national perinatal 131 
survey, few questions focused on flu prevention, and we did not evaluate women’s views about 132 
vaccination and barriers to it in great detail. Women were interviewed after birth, about three months 133 
after the vaccination campaign. However memory errors were unlikely because going to a vaccination 134 
center was the women’s decision and was not easily forgotten (travel to an unusual location, long wait 135 
times). 136 
The vaccination rate in our study (29.3%) was higher than the estimate by the agency that monitored 137 
vaccination coverage (22.7%). The latter was obtained by comparing the number of invitations sent to 138 
to the number of women vaccinated in these centers [12]. It is known that some pregnant women who 139 
were vaccinated in a center were not recorded in the campaign's monitoring system [10]. Some others 140 
may have been vaccinated in the hospital where they had prenatal visits. Moreover, our sample 141 
included women in the 2
nd
 trimester during the vaccination campaign, while vouchers were sent to 142 




 trimesters; those in their 3
rd
 trimester may have delivered before 143 
they were able to be vaccinated or were too tired to travel and stand in line for a vaccination. 144 
Rates of vaccination among pregnant women were higher than 50% in Quebec and Norway, around 145 
50% in Finland and the USA, and around 25% in the UK, while they were much lower in some other 146 
countries [8,16-18]. In France the priority given to pregnant women had an effect, for their vaccination 147 
rates were clearly higher than those of the general population (7.9%) [12]. Nonetheless, this rate was 148 
lower than in many other countries and did not exceed 50% among women who had jobs at high risk 149 
of exposure to and transmission of influenza. The rates observed among health care workers were 150 
rather low and suggest that these professionals were not always aware of the utility of vaccination 151 
[11,19].   152 
 Countries made very different choices in implementing their campaign, and these could have had an 153 
effect on population adhesion. Pregnant women in Canada were directed mainly to vaccination 154 
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centers [17], in Australia to their GPs [20], and in the US to either a doctor’s office, clinic or health 155 
center [21]. In France, vaccination was organized in ad hoc centers, mainly to avoid wasting vaccine 156 
doses and to deal with the lack of storage capacity in doctors' offices [22]. The health insurance fund 157 
sent all pregnant women a personal notification. This was possible because pregnant women must be 158 
registered to receive reimbursement of prenatal care expenses. In our study, very few women did not 159 
receive the invitation. This direct contact gave all women the opportunity to get similar information 160 
about the vaccination campaign. Nonetheless, the exclusion of personal health care providers from the 161 
vaccination campaign may have been a ‘missed opportunity to increase vaccination uptake’ [23]; for 162 
example French GPs play a key role in vaccination and management of seasonal influenza and had a 163 
positive attitude towards A(H1N1) vaccination. The involvement of obstetricians/gynecologists and 164 
midwives would have made vaccination easier, as pregnant women have prenatal visits at least once 165 
a month [13]. For instance, a program, which actively involved prenatal care providers and maternity 166 
units, resulted in a 77% vaccination rate in an American county [24]. The participation of care 167 
providers might also have resulted in wider vaccination coverage for the women with additional risk 168 
factors for complications, generally known to their doctor.  169 
Preventive behavior, such as not smoking and attending antenatal classes, were strong predictors of 170 
vaccination because women take these actions mainly on their own initiative, in the same way as they 171 
went for this vaccination. We also found that high educational level was a major factor associated with 172 
vaccination among pregnant women [21,25-26]. Material and financial constraints do not appear to 173 
have played an important role, as very few women reported that practical reasons explained why they 174 
were not vaccinated. The importance of the sociocultural environment may reflect women's ability to 175 
analyze the discordant information put forward by the media and public agencies during that period.  176 
The decision to accept A(H1N1) vaccination depended on many factors: the perception of the risk of 177 
being infected by this virus, the perception of the consequences of this flu, worries about vaccine 178 
safety, and distrust in the vaccine's effectiveness [11,21,26-29]. These perceptions and worries were 179 
reinforced among pregnant women because of the potential consequences for the fetus’ development 180 
in utero. Knowing all of the reasons that women refused vaccination is essential for clarifying complex 181 
information, guiding the messages of information campaigns directed at pregnant women, and 182 
developing recommendations for healthcare providers. For instance quality websites with validated 183 
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and frequently updated information or telephone services specialized in counseling pregnant women 184 
[17,28] were especially useful tools for information diffusion in Canada during the pandemic.    185 
 186 
CONCLUSION 187 
The campaign to vaccinate pregnant women against pandemic flu did not meet its objective in France. 188 
The initiative for vaccinations was left mainly to women and led to low vaccination coverage, strong 189 
social differences in uptake and no special protection for women at the highest risk of complications. 190 
Confronted with a novel and urgent situation, health authorities had difficulties developing policies 191 
quickly based on limited evidence. The evaluation of these policies is thus essential to help plan for 192 
future pandemics [22,30-31]. Lessons learned can also be applied to other vaccination policies, such 193 
as for the seasonal flu vaccine, which is expected to be recommended for use during pregnancy in 194 
France.  195 
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95% CI p 
Age (years)   <0.0001   <0.0001 
<24 2229 13.0  0.72 0.61-0.84  
25-29 4441 26.7  1   
30-34 4124 36.7  1.29 1.16-1.43  
35 + 2529 36.5  1.50 1.32-1.70  
       
Parity   <0.0001   <0.0001 
0  5916 28.7  1   
1-2 6425 31.4  1.26 1.13-1.40  
3+ 995 19.1  1.07 0.86-1.33  
       
Risk factors for complications   <0.0001   0.4291 
No 11866 30.1  1   
Yes 1587 23.3  0.94 0.82-1.08  
       
Family situation   <0.0001   0.0001 
Married & cohabiting with partner 6232 33.1  1   
Cohabiting  6196 28.3  0.88 0.80-0.96  
Not cohabiting 958 12.6  0.64 0.50-0.80  
       
Educational level   <0.0001   <0.0001 
Middle school or less 3720 14.7  1   
High school   2681 19.0  1.06 0.91-1.23  
Some college 2875 30.7  1.56 1.36-1.80  
College 2368 42.2  2.33 2.00-2.70  
Postgraduate 1750 57.0  4.08 3.46-4.81  
       
Maternal country of birth   <0.0001    
France 11.043 31.8  1  <0.0001 
Outside of France 2397 18.0  0.61 0.53-0.70  
       
Employment during pregnancy   <0.0001   0.0319 
No 3885 17.3  0.88 0.78-0.99  
Yes 9448 34.4  1   
       
Occupation characteristics   <0.0001   0.003 
Contact with children 774 51.0  1.26 1.06-1.49  
Healthcare worker 818 39.5  1.23 1.04-1.45  
Other (2) 11861 27.2  1   
       
Number of visits   <0.0001   0.2712 
<Minimum(3) 466 14.8  0.73 0.52-1.01  
Minimum or +1 2288 27.8  1   
Minimum +2 or +3 4450 30.9  0.98 0.86-1.12  
Minimum +4 or more 6037 30.3  0.96 0.85-1.09  
       
Place of care   <0.0001   0.0015 
Mainly public 9696 27.3  1   
Mainly private 3757 34.5  1.17 1.06-1.28  
       
Main healthcare provider      <0.0001 
Ob-gyn 9574 32.4 <0.0001 1   
General practitioner 2904 21.4  0.78 0.69-0.88  
Other 697 21.4  0.82 0.66-1.02  




Table I (continued). Odds Ratios for vaccination adjusted for all variables in the table 296 
 297 




95% CI p 
Folic acid consumption 
  <0.0001   <0.0001 
No 
9246 25.6  0.70 0.63-0.77  
Yes 
3286 41.8  1   
 
      
Smoking during pregnancy 
  <0.0001   0.0476 
No 





 0.88 0.77-1.00  
Prenatal classes 
  <0.0001   <0.0001 
No 
6941 21.4  0.68 0.62-0.76  
Yes 
6473 37.9  1   
 298 
(1) adjusted for all variables in the table and region (p<0.001), N=11,685 299 
(2) other occupation or no occupation during pregnancy 300 
(3) 7 visits for a full term pregnancy according to French regulation 301 
  302 
 303 
 304 
